Core Insights - Ailux Shanghai, a subsidiary of Crystal Tech Holdings, has entered into a strategic collaboration with Eli Lilly to accelerate the discovery and development of bispecific antibodies for various diseases [1] Collaboration Details - The partnership allows Eli Lilly to utilize Ailux's AI-driven bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developmental analysis [1] - Eli Lilly can nominate targets for bispecific antibody design and gain access to Ailux's patented platform for internal use [1] - The collaboration includes upfront payments and milestone payments totaling several tens of millions of dollars, with a potential total value of up to $345 million, including development, regulatory, and commercial milestone payments [1] Company Background - Crystal Tech was founded in 2015 by three physicists from MIT and operates as an innovative R&D platform driven by quantum physics, artificial intelligence, and robotics [1] - The company provides digital and intelligent R&D solutions for various industries, including pharmaceuticals, materials science, agricultural technology, energy, new chemicals, and cosmetics [1]
晶泰控股(02228.HK)子公司AILUX宣布与礼来战略合作赋能(AI驱动)双特异性抗体开发